Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Current Insights and Future Directions
Pancreatic Cancer (PC) is a devastating malignancy with a poor prognosis and in-creasing morbidity. Current treatment strategies have limited efficacy in improving patient survival. Metabolic reprogramming is a hallmark of cancer and plays a key role in the pro-gression and maintenance of PC. PC cells exhibit a unique glutamine metabolism that is dis-tinct from other cancer types. The non-classical pathway of glutamine metabolic reprogram-ming plays a "permissive role" in the survival and proliferation of PC cells, mainly by affect-ing the redox homeostasis of the cells. In this review, we compare and contrast the canonical and non-canonical glutamine metabolic pathways and highlight recent advances in targeting non-canonical glutamine metabolism for therapeutic intervention. This may provide novel in-sights and opportunities for exploiting glutamine metabolic reprogramming in PC treatment.
Authors
- Chengxia Kan (ORCID: https://orcid.org/0000-0002-4593-0303)
- Yuqun Wang
- Mingling Wang
- Xiaodong Sun (ORCID: https://orcid.org/0000-0001-7775-2823)
- Fangbing Ren
- Kai‐Liang Zhang
- Hongxi Sun
- Wenqiang Zhang (ORCID: https://orcid.org/0000-0002-0317-3914)
- Yanhui Ma
- Fang Han (ORCID: https://orcid.org/0000-0003-4130-3625)
Institutions
- Second Hospital of Shandong University (CN)
Publication Details
- Journal
- Current Cancer Drug Targets
- Published
- 2025-01-22
- DOI
- https://doi.org/10.2174/0115680096357993241206072609
- Citations
- 1
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94